Product
MAB-22
1 clinical trial
1 indication
Indication
Healthy ParticipantsClinical trial
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® Sourced From the European Union and United States in Healthy Male ParticipantsStatus: Not yet recruiting, Estimated PCD: 2025-07-01